SCYNEXIS, Inc. Cash and Restricted Cash
SCYNEXIS, Inc. (SCYX) had Cash and Restricted Cash of $10.68 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.68M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.86M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21.45M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.99M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $10.68M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $36.86M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $21.45M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $14.99M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $11.26M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $7.49M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $16.59M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $29.27M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $26.54M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $36.02M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $34.59M 10-K · filed 2026-03-04 |
| 2023-09-30 | $44.62M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $58.50M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $27.13M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $46.03M 10-K · filed 2025-03-12 |
| 2022-09-30 | $68.84M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $118.91M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $95.43M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $104.70M 10-K · filed 2024-03-28 |
| 2021-09-30 | $100.33M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $112.72M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $92.28M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $93.31M 10-K · filed 2023-03-31 |
| 2020-09-30 | $29.77M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $34.29M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $20.53M 10-Q · filed 2021-05-17 |
| 2019-12-31 | $42.19M 10-K · filed 2022-03-29 |
| 2019-09-30 | $11.89M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $19.48M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $13.28M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $11.77M 10-K · filed 2021-03-29 |
| 2018-09-30 | $16.41M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $7.10M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $27.55M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $11.47M 10-K · filed 2020-03-11 |
| 2017-09-30 | $8.75M 10-Q · filed 2018-11-13 |
| 2017-06-30 | $7.45M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $19.91M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $35.66M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |